Interferon-Induced Thrombotic Microangiopathy

Kundra, Ajay; Andrei, Mirela; Wang, Jen C.

doi:10.5772/intechopen.74226

Cited by 1 publication

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with DS have a 4 to 6-fold higher risk of developing auto-immune conditions, mostly thyroid disorders, diabetes and coeliac disease, thought to stem from an innate T-cell dysfunction with overproduction and oversensitivity of cytokines associated with auto-immunity (IFN, IL17, etc) and resisting to Treg suppression. These immune alterations do not seem to confer an increased risk of developing ITP, but interferon as a drug is a known precipitating factor of immune TTP [13], suggesting altered IFN signalling in DS could theoretically predispose to immune TTP, TTP in pa passive transfer of anti-ADAMTS13 antibodies through intravenous (IVIG) as hemolytic anemia developed after the infusion. TTP is a rare but serious condition associating thrombocytopenia and hemolytic anemia.…”

Section: Discussionmentioning

confidence: 99%

Thrombocytopaenia and Down Syndrome – What about the Usual Suspects?

Céline,

Claire,

Benoit

et al. 2023

SunText Rev Case Rep Image

View full text Add to dashboard Cite

Down syndrome is a chromosomal disorder renowned for conferring a predisposition to auto-immune and hematological conditions; hematological abnormalities in this population should prompt investigations to exclude malignancy, but comprehensive differential diagnosis should be broadened to other pathologies. A 15 months-old infant with Down syndrome presented with isolated moderate thrombocytopenia during an episode of upper respiratory tract infection. Clinical examination was unremarkable except for mild hepatomegaly and diffuse petechial rash. A bone marrow aspiration showed no malignant infiltration. Intravenous immunoglobulins showed little benefit over the course of the following 7 days. The patient secondarily developed hemolytic anemia. ADAMTS13 activity was undetectable, and plasmatic inhibitors were detected confirming the hypothesis of immune thrombotic thrombocytopenic purpura (TTP), triggered by an infection. Daily plasmapheresis were started with immediate but short-lived benefit, and TTP persistently recurred every 48h after interruption of exchanges, warranting initiation of treatment with Rituximab and enabling the achievement of long-term remission. Acquired TTP is an extremely rare entity in children below 9 years of age (<1/1.000.000), and can be life-threatening due to the formation of micro thrombi occluding terminal circulation leading to organ damage and dysfunction. Prompt recognition of this entity is important to avoid long-term damages. Altered IFN signaling in Down syndrome could wn syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%